Article summary line: Several commercially available SARS-CoV-2 ELISAs show limited

specificity when applied to serum panels of African origin.

Running title: SARS-CoV-2 IgG ELISA specificity

Keywords: SARS-CoV-2, seroepidemiologic studies, immunoglobulin G, Enzyme-Linked

Immunosorbent Assay, specificity, Africa

Title:

Limited specificity of commercially available SARS-CoV-2 IgG ELISAs in serum

samples of African origin

Authors:

Petra Emmerich, Carolin Murawski, Christa Ehmen, Ronald von Possel, Neele Pekarek, Lisa

Oestereich, Sophie Duraffour, Meike Pahlmann, Nicole Struck, Daniel Eibach, Ralf

Krumkamp, John Amuasi, Oumou Maiga-Ascofare, Raphael Rakotozandrindrainy, Danny

Asogun, Yemisi Ighodalo, Simone Kann, Jürgen May, Egbert Tannich, Christina

Deschermeier

Affiliations:

Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany (P. Emmerich,

C. Murawski, C. Ehmen, R. von Possel, N. Pekarek, L. Oestereich, S. Duraffour,

M. Pahlmann, N. Struck, D. Eibach, R. Krumkamp, J. May, E. Tannich, C. Deschermeier)

University of Rostock, Rostock, Germany (P. Emmerich)

German Center for Infection Research (DZIF), Hamburg – Lübeck – Borstel – Riems,

Germany (L. Oestereich, S. Duraffour, M. Pahlmann, N. Struck, D. Eibach, R. Krumkamp,

O. Maiga-Ascofare)

Kumasi Centre for Collaborative Research in Tropical Medicine, Kumasi, Ghana (J. Amuasi,

O. Maiga-Ascofare)

University of Antananarivo, Antananarivo, Madagascar (R. Rakotozandrindrainy)

Irrua Specialist Teaching Hospital, Irrua, Nigeria (D. Asogun, Y. Ighodalo)

Medical Mission Institute, Würzburg, Germany (S. Kann)

National Reference Centre for Tropical Pathogens, Hamburg, Germany (E. Tannich)

Corresponding author: Christina Deschermeier

Mailing address: Bernhard Nocht Institute for Tropical Medicine, Bernhard-Nocht-Str. 74,

20359 Hamburg

Email address: descherm@bnitm.de

Phone number: +49 (40) 42818-438

ORCiD ID: 0000-0002-8309-7877

ABSTRACT

Specific serological tests are mandatory for reliable SARS-CoV-2 seroprevalence studies but

assay specificity may vary considerably between populations due to interference of immune

responses to other pathogens. Here, we assess the false positive rates obtained with four

commercially available IgG ELISAs in serum/plasma panels originating from three different

African countries.

By November 1st 2020, 1,324,258 laboratory-confirmed SARS-CoV-2 infections and 29,785

deaths caused by COVID-19 have been reported from the WHO Africa region (1). Currently,

community transmission is observed in almost all African countries including Tanzania,

Ghana, Madagascar, Nigeria, Kenya, South Sudan, Burundi, and Uganda (1). To correctly

determine the actual exposure of the population to SARS-CoV-2 and to draw reliable

conclusions on morbidity and case fatality rates, highly sensitive and specific serological

tests are mandatory.

Up to now, a plethora of ELISA tests for detection of anti-SARS-Cov-2 antibodies has been

developed and commercialized (2, 3). Although performance data for several of these assays

have been rapidly communicated by different laboratories (4-7), still only few reports are

available on the applicability of these tests on African serum panels (8, 9). Here, assay

specificity may be challenged by previous or current infections with other endemic pathogens

like other coronaviruses (10), Dengue virus (11), or *Plasmodium spp. (12)*.

THE STUDY

To assess the specificities of commercially available SARS-CoV-2 IgG ELISA tests in sample

panels of different origin*, a priori* SARS-CoV-2 IgG negative sample panels (**Table 1**)

collected from symptom-free donors before 2019 in Africa (Ghana, Madagascar, Nigeria),

South America (Colombia) and Europe (Germany) were analyzed with the Euroimmun Anti-

SARS-CoV-2-NCP IgG ELISA (Euroimmun, Germany), the Euroimmun Anti-SARS-CoV-2

IgG ELISA (Euroimmun, Germany), the EDI[TM] Novel Coronavirus COVID-19 IgG ELISA

(Epitope Diagnostics, US), and the Mikrogen *recom*Well SARS-CoV-2 IgG ELISA (Mikrogen,

Germany) (**Appendix Table 1**). Assays were performed and evaluated according to the

manufacturers' instructions.

While IgG ELISA specificities where good to excellent for pre-COVID-19 sample panels

originating from Colombia, Madagascar, and Germany, increased false positive rates were

observed in *a priori* SARS-CoV-2 IgG negative sera from Ghana and Nigeria (**Figure 1,**

Table 2). Thereby, the index values obtained with the Euroimmun NCP IgG ELISA and the

EDI^TM IgG ELISA, both employing recombinant nucleocapsid protein (NCP) as antigen,

showed a clear correlation (**Appendix Figure 1A, 1C, 1E, 1G),** while only 15 samples

(Ghana: n=7, Nigeria: n=8), were concordantly classified as positive by both the NCP-based

and the spike/S1-based Euroimmun IgG ELISA (**Appendix Figure 1B, 1D, 1F, 1H, Figure**

2A). For all 15 sera, IgG immunofluorescence testing using SARS-CoV-2-infected Vero cells

(13) was negative, and no or only weak inhibition of receptor binding was observed in a

SARS-CoV-2 surrogate virus neutralizing test (sVNT, Genscript, US) (**Figure 2A**).

One possible cause of the observed limited specificity of SARS-CoV-2 IgG ELISAs may be

cross-reaction with antibodies elicited by previous infections with other coronaviruses. To

investigate this possibility, we assayed the complete sample panel for IgG antibodies binding

to the C-terminal dimerization domains of the four common cold coronavirus NCPs using an

in-house IgG ELISA protocol ((14), **Appendix Methods, Figure 2B-E**).

As can be expected due to the worldwide occurrence of the common cold coronaviruses, IgG

antibodies interacting with the C-terminal domains of OC43, HKU1, NL63, and 229E NCP

were detected in considerable fractions of all sample panels, including those for which good

or excellent SARS-CoV-2 ELISA specificity has been observed (**Figure 2B-E)**. Nevertheless,

the most challenging sample panel originating from Nigerian donors displayed the by far

highest percentage of OC43-ELISA-reactive samples (43.3 %, **Figure 2B**). In a line blot

(Euroline Anti-SARS-CoV-2 Profile IgG, Euroimmun), all 15 serum samples from Ghana

(n=7) and Nigeria (n=8) showing up positive in both the spike/S1-based and the NCP-based

Euroimmun IgG ELISA generated strong signals with OC43 NCP (**Figure 2A**). In addition,

antibodies binding to SARS-CoV-2 spike S2 were found in 6/7 Ghanaian and 3/8 Nigerian

samples (**Figure 2A**). 7/8 of the Nigerian sera, but only 2/7 of the Ghanaians samples tested

positive in the in-house OC43 ELISA employing a truncated NCP lacking the N-terminal

domain as antigen. Therefore, at least some of the observed false positive signals could be

due to previous infections with other coronaviruses sharing B cell epitopes with both OC43

and SARS-CoV-2.

Recently, Lustig *et al. (11)* reported false positive results of the Euroimmun Anti-SARS-CoV-

2 IgA and IgG ELISAs in sera originating from donors with acute or past dengue virus

(DENV) infection. In our study, 29 (21.6%) of the 134 Colombian donors tested positive in the

SD Bioline Dengue Duo IgG Rapid Test (Alere/Abbott, USA), indicating a high titer of anti-

DENV IgG antibodies (15). Indeed, two of the three Colombian sera testing positive in the

spike-based Euroimmun Anti-SARS-CoV-2 ELISA (but negative in the nucleoprotein-based

SARS-CoV-2 ELISAs) belonged to this subgroup.

In addition, hypergammaglobulinemia resulting from polyclonal B-cell activation induced by

pathogens like plasmodium can challenge assay specificity as has already been shown for a

commercially available ZIKV IgG ELISA (12). Information about *Plasmodium* parasitemia

was only available for one of the Ghanaian (55/150 samples with microscopically detectable

parasitemia) and the Madagascan (4/167 Plasmodium-PCR positive samples) panels. Here,

a reduced specificity in Ghanaian parasitemic vs. non-parasitemic samples was observed for

the Euroimmun Anti-SARS-CoV-2-NCP-IgG ELISA (83.6% (95% CI: 71.5%-91.4%) vs.

94.7% (95% CI: 88.0%-98.0%), p = 0.0387), but not for the other SARS-CoV-2 IgG ELISAs

(**Appendix Table 2**).

LIMITATIONS OF THE STUDY

Our study has some major limitations that have to be acknowledged when interpreting the

presented data. First of all, sample panels originating from previous studies with different

scientific objectives had to be used for the analysis; therefore, the panels do not reflect

representative cross-sections of the respective countries' populations and also comparability

between sample panels is limited due to differences in age and sex of donors. Although in total 600 African samples have been analyzed, the number of samples per country giving rise to false positive SARS-CoV-2 IgG assay results is still relatively small, impeding statistical analyses. Furthermore, limited accessible sample volumes prevented us from performing material-intensive assays as the SD Bioline Dengue Duo IgG Rapid Test or *Plasmodium*-specific RT-PCR for the complete panel.

CONCLUSIONS

In accordance with evaluation studies recently published by other authors (4-6), the commercially available SARS-CoV-2 IgG ELISAs displayed a good to excellent specificity when applied to serum panels originating from European donors. In contrast, significantly increased false positive rates were observed in African pre-COVID-19 serum panels originating from Ghana and Nigeria. A similar result has been found recently for serum samples from febrile patients from Benin (9). Possible causes for this observation are cross-reactive antibodies elicited by previous infections with endemic viruses (in particular other coronaviruses), polyclonal B-cell activation induced e.g. by plasmodium infection, or a combination thereof.

Based on these findings, the following recommendations should be considered when planning and performing SARS-CoV-2 seroprevalence studies (not only) in Africa: 1) Prior to performance of seroprevalence studies, carefully assess background/false positive signals obtained with the chosen serological test(s) in the target population (using *a priori* SARS-CoV-2 IgG negative serum samples which were stocked before 2019). Be aware of potentially interfering/cross-reacting endemic pathogens and carefully interpret SARS-CoV-2 IgG test results in this context. 2) If necessary, combine information from two independent serological tests employing different antigens. 3) Re-evaluate samples generating a positive ELISA result by SARS-CoV-2 neutralization testing.

Further studies will be necessary to assess sensitivity of the commercially available assays

in detecting anti-SARS-CoV2 IgG antibodies induced by SARS-CoV-2 infection in African

COVID-19 patients and to optimize assay specificity in sera from African donors.

ACKNOWLEDGMENTS

The authors thank M. Panning for providing common cold coronavirus RNAs. J. Hansen is

thanked for expert technical assistance.

FUNDING

The study was supported by the German Federal Ministry of Education and Research (Grant

no. 01KI20210), the German Research Foundation (DFG, GU 883/4-1 and GU 883/5-1), by

the German Federal Ministry of Health through support of the WHO Collaborating Centre for

Arboviruses and Hemorrhagic Fever Viruses at BNITM (agreement ZMV I1-2517WHO005),

through the Global Health Protection Program (agreement ZMV I1-2517GHP-704), and

through the COVID support agreement ZMVI1-2520COR001. Collection of Colombian serum

samples was supported by the European Regional Development Fund (ERDF), project

number BWF/H/52228/2012/13.10.10-1/3.4. The funders had no role in study design, data

collection and analysis, decision to publish, or preparation of the manuscript.

AUTHOR BIOGRAPHY

Dr. Emmerich is a laboratory group leader at the Bernhard Nocht Institute for Tropical

Medicine in Hamburg, Germany. Her research is focused on diagnostics of viral infectious

diseases.

REFERENCES

1. WHO. COVID-19 Weekly Epidemiological Update, 01Nov2020

2. FIND. https://www.finddx.org/covid-19/sarscov2-eval-immuno/

3. University JH. https://www.centerforhealthsecurity.org/resources/COVID-19/serology/Serology-based-tests-for-COVID-19.html. 2020.

4. Geurts van Kessel CH, Okba NMA, Igloi Z, Bogers S, Embregts CWE, Laksono BM, et al. An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment. Nature communications. 2020;11(1):3436.

5. Kruttgen A, Cornelissen CG, Dreher M, Hornef M, Imohl M, Kleines M. Comparison of four new commercial serologic assays for determination of SARS-CoV-2 IgG. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 2020;128:104394.

6. Pflüger LS, Bannasch JH, Brehm TT, Pfefferle S, Hoffmann A, Nörz D., et al. Clinical evaluation of five different automated SARS-CoV-2 serology assays in a cohort of hospitalized COVID-19 patients. Journal of Clinical Virology. 2020.

7. Weidner L, Gansdorfer S, Unterweger S, Weseslindtner L, Drexler C, Farcet M, et al. Quantification of SARS-CoV-2 antibodies with eight commercially available immunoassays. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 2020;129:104540.

8. Chibwana MG, Jere KC, Kamn'gona R, Mandolo J, Katunga-Phiri V, Tembo D, et al. High SARS-CoV-2 seroprevalence in health care workers but relatively low numbers of deaths in urban Malawi. MedRxiv preprint, https://doi.org/10.1101/2020.07.30.20164970. 2020.

9. Yadouleton A, Sander A, Moreira-Soto A, Tchibozo C, Hounkanrin G, Badou Y, et al. Limited specificity of serologic tests for SARS-CoV-2 antibody detection, Benin, Western Africa. medRxiv preprint, https://doi.org/10.1101/2020.06.29.20140749. 2020.

10. Tso FY, Lidenge SJ, Pena PB, Clegg AA, Ngowi JR, Mwaiselage J., et al. High

prevalence of pre-existing serological cross-reactivity against SARS-CoV-2 in sub-

Saharan Africa. International Journal of Infectious Diseases.

https://doi.org/10.1016/j.ijid.2020.10.104. 2020

11. Lustig Y, Keler S, Kolodny R, Ben-Tal N, Atias-Varon D, Shlush E, et al. Potential

antigenic cross-reactivity between SARS-CoV-2 and Dengue viruses. Clin Infect Dis.

2020.

12. Van Esbroeck M, Meersman K, Michiels J, Arien KK, Van den Bossche D. Letter to

the editor: Specificity of Zika virus ELISA: interference with malaria. Euro surveillance

: bulletin Europeen sur les maladies transmissibles = European communicable

disease bulletin. 2016;21(21).

13. Reisinger EC, von Possel R, Warnke P, Geerdes-Fenge HF, Hemmer CJ, Pfefferle S,

et al. Screening of Mothers in a COVID-19 Low-Prevalence Region: Determination of

SARS-CoV-2 Antibodies in 401 Mothers from Rostock by ELISA and Confirmation by

Immunofluorescence. Deutsche medizinische Wochenschrift. 2020.

14. Schmitz H, Gabriel M, Emmerich P. Specific detection of antibodies to different

flaviviruses using a new immune complex ELISA. Med Microbiol Immunol.

2011;200(4):233-9.

15. Blessmann J, Winkelmann Y, Keoviengkhone L, Sopraseuth V, Kann S, Hansen J, et

al. Assessment of diagnostic and analytic performance of the SD Bioline Dengue Duo

test for dengue virus (DENV) infections in an endemic area (Savannakhet province,

Lao People's Democratic Republic). PLoS One. 2020;15(3):e0230337.

TABLES

Table 1. Sample panels used in the study

serum panel	Ghana 1	Ghana 2	Madagascar	Nigeria	Colombia	Germany
number	150	133	167	150	134	148
sampling year	2014 - 2015	1999	2010	2018	2014	2004 - 2015
sample type	serum	serum	plasma	serum	serum	serum
donors	children	teens, adults	pregnant women	adults	adults	adults
age (median, IQR)	6 (3 – 7)	22 (16 – 45) *	23 (20 – 30)	41 (30 – 58)**	27 (23 – 36)	39 (28 – 48)***
sex m/f (n (%))	72/78 (48/52)	61/72 (46/54)	0/167 (0/100)	71/79 (47/53)	55/79 (41/59)	79/35 (69/31)***
sampling site	Agogo	villages in the central region of Ghana	coastal (n=89) and highland (n=68) regions	Irrua	Valledupar	Hamburg
Plasmodium spp. **positive (n (%))**	55 (37.7 %) [#]	not tested	4 (2.4%) [#]	not tested	not tested; no previous infections reported	not tested
SD Bioline Dengue Duo Rapid Test IgG pos (n (%))	not tested	not tested	not tested	not tested	29 (21.6%)	not tested

M: male, f: female, IQR: interquartile range.

Collection of samples has been approved by the Ethics Committees of the Kwame Nkrumah

University of Science and Technology (Kumasi/Ghana), the Comité d'ethique de la Vice

Primature Chargée de la Santé Publique (Antananarivo/Madagaskar), the Irrua Specialist

Teaching Hospital (Irrua/Nigeria), the Hospital Rosario Pumarejo de Lopez

(Valledupar/Colombia), and the Medical Association Hamburg/Germany. All studies complied

with the Declaration of Helsinki. Written informed consent was obtained from all individuals

or, in case of minors, from parents or legal guardians before enrollment. Data privacy

protection was guaranteed by anonymization of samples.

*n=89 (exact age information not available for 43 donors (all 43: age ≥ 18 years))

**n=149 (age information not available for one donor)

***n=114 (sex and exact age information not available for 34 donors (all 34: age ≥ 18 years))

[#]Parasitemic samples were identified by microscopy (Ghana) and plasmodium-specific RT-

PCR (Madagascar), respectively.

Table 2. SARS-CoV-2 IgG ELISA specificities

Antigen				Euroimmun Anti-SARS-CoV-2-NCP-ELISA IgG			Euroimmun Anti-SARS-CoV-2-ELISA IgG			*EDI*™ Novel Coronavirus COVID-19 IgG ELISA kit			Mikrogen *recom*Well SARS-CoV-2 IgG		
				NCP (modified)			Spike S1 domain			NCP			NCP		
Ghana 1 (n=150)	pos	bl	neg	14	11	125	12	1	137	24	17	109	7	7	136
	specificity (95% CI)			90.7 (84.8 – 94.5)			92.0 (86.4 – 95.5)			84.0 (77.2 – 89.1)			95.3 (90.5 – 97.9)		
Ghana 2 (n=133)	pos	bl	neg	34	21	78	4	3	126	39	15	79	22	10	101
	specificity (95% CI)			74.4 (66.4 – 81.1)			97.0 (92.3 – 99.1)			70.7 (62.4 – 77.8)			83.5 (76.2 – 88.9)		
Madagas-car (n=167)	pos	bl	neg	2	4	161	3	0	164	11	10	146	1	3	163
	specificity (95% CI)			98.8 (95.5 – 99.9)			98.2 (94.6 – 99.6)			93.4 (88.5 – 96.4)			99.4 (96.3 – 100.0)		
Nigeria (n=150)	pos	bl	neg	42	18	90	14	7	129	91	19	40	26	6	118
	specificity (95% CI)			72.0 (64.3 – 78.6)			90.7 (84.8 – 94.5)			39.3 (31.9 – 47.3)			82.7 (75.8 – 87.9)		
Colombia (n=134)	pos	bl	neg	0	1	133	3	1	130	1	3	130	3	2	129
	specificity (95% CI)			100.0 (96.6 – 100.0)			97.8 (93.3 – 99.5)			99.2 (95.5 – 100.0)			97.8 (93.3 – 99.5)		
Germany (n=148)	pos	bl	neg	0	4	144	2	3	143	2	1	145	6	0	142
	specificity (95% CI)			100.0 (97.0 – 100.0)			98.6 (94.9 – 99.9)			98.6 (94.9 – 99.9)			95.9 (91.2 – 98.3)		

pos/bl/neg: number of samples rated as positive (pos), borderline (bl), and negative (neg) by the respective test. CI: confidence interval. For calculation of specificities, both negative and borderline results were classified as "not positive".

	FIGURE LEGENDS

	Figure 1. SARS-CoV-2 IgG ELISA results. Index values obtained for serum/plasma

	samples collected before 2019 in three different African countries (Ghana panel 1 (n=150),

	Ghana panel 2 (n=133), Madagascar (n=167), Nigeria (n=150)), Colombia (n=134), and

	Germany (n=148) with **(A)** the Euroimmun Anti-SARS-CoV-2-NCP IgG ELISA, **(B)** the

	Euroimmun Anti-SARS-CoV-2 IgG ELISA, **(C)** the EDI Novel Coronavirus COVID-19 IgG

	ELISA, and **(D)** the Mikrogen *recom*Well SARS-CoV-2 IgG ELISA. Dotted lines represent

	negative and positive cut-off values, respectively. Grey shading indicates index values rated

	as "borderline" according to the manufacturers' instructions. Diamonds represent index

	values obtained for two IgG positive COVID-19 patient sera sampled on day 19 post onset of

	symptoms (dark grey: SARS-CoV-2 IgG IIFT titer 1:640, light grey: SARS-CoV-2 IgG IIFT

	titer 1:160) and one negative control serum; error bars represent standard deviation of n=13

	(A, C) and n=14 (B, D) independent measurements, respectively.

	Figure 2. (A) ELISA, sVNT and line blot results for sera testing positive in both the

	Euroimmun spike/S1- and NCP-based IgG ELISA. Serum samples (Ghana 1 (G1): n=4,

	Ghana 2 (G2): n=3, Nigeria (N): n=8)) were tested using the SARS-CoV-2 sVNT (Genscript)

	and the Euroline Anti-SARS-CoV-2 Profile IgG (Euroimmun) according to the manufacturer's

	instructions. Rating of index values (iv): Euroimmun ELISA: negative: iv < 0.8, borderline; 0.8

	≤ iv < 1.1, positive: iv ≥ 1.1; Line blot: negative: iv < 0.6, borderline: 0.6 ≤ iv < 1.0, positive: iv

	≥ 1.0; in-house ELISA: negative: iv < 0.7, borderline: 0.7 ≤ iv < 1.3, positive: iv ≥ 1.3; sVNT:

	negative: % inhibition < 20.0, borderline; 20.0 ≤ % inh < 30.0, positive: % inh ≥ 30.0; CTD: C-

	terminal domain; dark grey fields: positive; light grey fields: borderline. **(B) - (E) Common**

	cold CoVs ELISA results. Index values obtained for the sample panels from Ghana (1:

	n=150, 2: n=133), Madagascar (n=167), Nigeria (n=150), Colombia (n=134), and Germany

	(n=148) using an in-house IgG ELISA protocol employing the C-terminal dimerization domain

	of **(A)** OC43 NCP, **(B)** HKU1 NCP, **(C)** NL63 NCP, and **(D)** 229E NCP as antigen. Bold

278   numbers: % of samples for which an iv ≥ 1.3 was obtained, numbers in brackets: 95%

279   confidence interval. Grey shading indicates ivs rated as "borderline" (0.7 ≤ iv < 1.3).

Figure 1

Figure 2

A

ID	sVNT % inh	Euroimmun ELISA SARS-CoV-2		Euroimmun Lineblot SARS-CoV-2			NCP				in-house ELISA NCP-CTD			
		NCP	S1	NCP	S1	S2	OC43	HKU1	NL63	229E	OC43	HKU1	NL63	229E
G1-1	1.9	1.2	2.0	0.4	3.1	3.5	5.0	0.7	0.1	0.1	1.5	0.5	0.1	0.1
G1-2	9.4	2.7	4.6	0.9	5.3	5.2	6.2	0.5	0.4	0.2	0.4	0.3	0.2	0.2
G1-3	10.0	1.4	2.5	1.1	3.6	1.9	5.1	0.2	0.6	0.5	0.2	0.2	0.3	0.2
G1-4	4.1	2.5	1.9	0.5	1.6	2.4	4.1	0.9	2.8	1.2	2.9	0.3	10.1	0.2
G2-1	25.6	1.8	1.2	0.9	1.0	0.6	1.6	0.2	0.3	0.4	0.6	0.2	0.2	0.1
G2-2	24.6	1.5	1.9	0.9	1.7	2.2	7.1	0.4	2.1	0.9	0.2	0.3	2.0	0.1
G2-3	21.2	1.3	1.2	1.4	2.4	4.3	7.3	0.2	0.8	0.2	0.2	0.3	0.2	0.1
N-1	24.4	3.6	1.8	3.7	1.3	1.0	5.3	0.3	1.0	2.8	5.3	0.2	6.0	0.2
N-2	10.7	4.9	1.3	2.3	0.4	0.3	6.2	0.4	1.4	0.5	1.5	0.2	0.2	0.2
N-3	23.7	4.4	7.7	1.1	6.8	5.6	7.2	2.7	1.4	0.8	7.5	2.8	0.6	0.3
N-4	28.4	4.9	1.5	3.3	1.8	0.8	4.1	1.0	3.0	2.2	1.4	0.6	7.4	0.3
N-5	19.4	2.6	1.4	0.3	0.7	0.2	5.8	0.5	1.1	0.7	1.5	0.4	0.3	0.2
N-6	21.5	2.1	2.1	1.2	1.6	0.2	4.2	0.3	0.7	3.5	4.3	0.9	1.1	2.6
N-7	27.7	1.7	2.2	1.3	2.2	2.3	5.1	0.9	1.5	0.7	7.4	2.9	9.8	2.0
N-8	28.3	1.4	1.2	0.4	1.0	0.3	5.0	1.0	1.2	0.7	1.0	0.7	0.9	0.3